NXTC NextCure Inc
Price (delayed)
$0.7842
Market cap
$21.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.09
Enterprise value
-$351,158
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune
Highlights
NXTC's debt is down by 12% year-on-year and by 3.6% since the previous quarter
NXTC's net income is up by 11% year-on-year and by 4.5% since the previous quarter
The quick ratio has plunged by 52% YoY but it has grown by 9% from the previous quarter
NextCure's equity has decreased by 40% YoY and by 12% QoQ
Key stats
What are the main financial stats of NXTC
Market
Valuations
Earnings
Shares outstanding
28.01M
Market cap
$21.96M
Enterprise value
-$351,158
Price to earnings (P/E)
N/A
Price to book (P/B)
0.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$63.08M
Net income
-$58.52M
EBIT
-$58.52M
EBITDA
-$54.93M
Free cash flow
-$45.03M
Per share
Balance sheet
Liquidity
EPS
-$2.09
EPS diluted
-$2.09
Free cash flow per share
-$1.61
Book value per share
$2.7
Revenue per share
$0
TBVPS
$3.23
Total assets
$90.35M
Total liabilities
$14.75M
Debt
$5.39M
Equity
$75.59M
Working capital
$70.02M
Debt to equity
0.07
Current ratio
9.07
Quick ratio
8.68
Net debt/EBITDA
0.41
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-53.7%
Return on equity
-62.5%
Return on invested capital
-68.3%
Return on capital employed
-71.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NXTC stock price
How has the NextCure stock price performed over time
Intraday
1.51%
1 week
-1.88%
1 month
-4.66%
1 year
-37.76%
YTD
1.71%
QTD
1.71%
Financial performance
How have NextCure's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$63.08M
Net income
-$58.52M
Gross margin
N/A
Net margin
N/A
NXTC's net income is up by 11% year-on-year and by 4.5% since the previous quarter
NextCure's operating income has increased by 9% YoY and by 4.7% from the previous quarter
Growth
What is NextCure's growth rate over time
Valuation
What is NextCure stock price valuation
P/E
N/A
P/B
0.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 11% YoY and by 4.6% from the previous quarter
The P/B is 64% lower than the 5-year quarterly average of 0.8 and 42% lower than the last 4 quarters average of 0.5
NextCure's equity has decreased by 40% YoY and by 12% QoQ
Efficiency
How efficient is NextCure business performance
NextCure's return on invested capital has decreased by 41% YoY and by 13% QoQ
NXTC's return on equity is down by 40% year-on-year and by 9% since the previous quarter
NXTC's ROA is down by 32% YoY and by 6% QoQ
Dividends
What is NXTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NXTC.
Financial health
How did NextCure financials performed over time
NXTC's current ratio has dropped by 52% year-on-year but it is up by 9% since the previous quarter
The quick ratio has plunged by 52% YoY but it has grown by 9% from the previous quarter
NXTC's debt is 93% smaller than its equity
NextCure's equity has decreased by 40% YoY and by 12% QoQ
The debt to equity is up by 40% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.